Conshohocken, PA, January 3, 2023
AUCTUS completes exit of PharmaLex in EUR 1.28bn transaction
Funds advised by AUCTUS Capital Partners AG sell a majority stake in the leading pharma services group PharmaLex to AmerisourceBergen Corporation. During the 8 years of AUCTUS investment and a successful buy-and-build strategy, PharmaLex has shown a double digit organic growth that was seconded by a decisive international buy-and-build strategy. 38 add-ons that supported the group in terms of rounding up the product portfolio, global reach and coverage of key clients helped PharmaLex to become the leading provider of specialized services for the life sciences industry.
PharmaLex is a global team of scientific, regulatory, and safety and compliance (GxP) experts that provide strategic guidance and regulatory support to biopharma companies throughout a product’s lifecycle. The company provides tech-enabled services ranging from clinical development consulting to marketing authorization, enabling clients to efficiently bring products to global markets and diverse patient populations.
Headquartered in Germany, PharmaLex has developed its global reach with a significant footprint in Europe and the U.S. and a growing presence in other parts of the world.
AmerisourceBergen’s acquisition of the PharmaLex Group will advance the company’s role as partner of choice for pharmaceutical partners by enhancing their global solutions to support clients across the pharmaceutical development and commercialization journey.
Dr. Nicolas Himmelmann, Partner with AUCTUS comments: “Over almost a decade we have helped PharmaLex to become the preferred partner for the global biopharma industry plus to shape its profile as the center of gravity attracting further specialists in the fragmented pharmaservice market to join the integrated group, paving the future growth path.”
The transaction was closed at year-end 2022. On the part of AUCTUS, the platform was managed by Dr. Nicolas Himmelmann and Benjamin Seifert.
About AmerisourceBergen
AmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the development and delivery of pharmaceuticals and healthcare products. As a leading global healthcare company, with a foundation in pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency and reliability for human and animal health. Our approximately 44,000 global team members power our purpose: We are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual revenue.
Informazioni su Auctus
Con oltre 400 investimenti negli ultimi 23 anni, AUCTUS è la società di investimento più attiva per le PMI europee. I nostri investimenti si concentrano su partecipazioni di maggioranza in aziende con un fatturato annuo compreso tra 10 e 150 milioni di euro.
AUCTUS è sinonimo di crescita organica sostenibile, ma anche di crescita inorganica attraverso le acquisizioni. Raggiungiamo questo obiettivo grazie a una partnership di fiducia con i dirigenti delle nostre aziende. Siamo specializzati nella creazione di gruppi di aziende di medie dimensioni di successo: creiamo leader di mercato. Gli oltre 35 esperti di investimenti di AUCTUS gestiscono attualmente 50 piattaforme di investimento in diversi settori economici. L'insieme delle partecipazioni della piattaforma, con un totale di oltre 200 singole aziende, genera un fatturato annuo di 3 miliardi di euro. >Le vendite e gli utili sono cresciuti del 10% all'anno per anni.
Il nostro lavoro di successo viene regolarmente premiato con prestigiosi riconoscimenti e classifiche internazionali.
